Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 8, 2025
Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025
Read more at globenewswire.com
